TerminatedNCT06202521Updated Jan 8, 2026Results posted

CX-4945 in Viral Community Acquired Pneumonia

A Phase 2 interventional study of CX-4945 (SARS-CoV-2 domain) and Placebo (SARS-CoV-2 domain) in Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia and Influenza With Pneumonia, sponsored by Senhwa Biosciences, Inc.. Terminated at 7 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Senhwa Biosciences, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated

The trial ended early in March 2025 due to changes in disease epidemiology, affecting patient availability and recruitment feasibility.

Phase: Phase 2
Study type: Interventional
Enrollment: 45
Allocation: Randomized
Ages: 18 Years and older
Sex: All

Study summary

This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated pneumonia. The subjects will be recruited into two domains, including SARS-CoV-2 and influenza virus domains. The study will compare the efficacy of Standard of Care (SOC) combined with CX-4945 against SOC paired with a placebo, utilizing a 1:1 allocation ratio in each domain.

Read the detailed description

Domain I: SARS-CoV-2 domain

Arm 1: CX-4945 (400 mg BID for 5 days) +SOC
Arm 2: Placebo + SOC

Domain II: Influenza virus domain

Arm 3: CX-4945 (400 mg BID for 5 days) +SOC
Arm 4: Placebo + SOC

Screening visit will collect health information and perform protocol specified tests to determine patients' eligibility. After screening visit, eligible subjects who fulfill all selection criteria for enrollment will be randomized into each of the arms. The CX-4945 will be administered at 400 mg BID for 5 days. Subjects will be followed up until Day 29.

Conditions studied

Community-acquired Pneumonia
SARS-CoV-2 -Associated Pneumonia
Influenza With Pneumonia

Browse trials for

Keywords

Covid-19
Influenza
Community-acquired Pneumonia

In context

Community-Acquired Pneumonia

82 studies on the registry are indexed under Community-Acquired Pneumonia; 51 are open to participants now.

This study's enrollment of 45 is below the median of 326 across 53 interventional studies indexed under Community-Acquired Pneumonia.

Browse Community-Acquired Pneumonia studies →

Lead sponsor

Senhwa Biosciences, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

Not currently hospitalized
Males or females aged ≥ 18 years at the time of signing the informed consent form (ICF)
Patients diagnosed with viral pneumonia, as determined by the investigator, who exhibit any of the subsequent criteria: presence of respiratory symptoms or fever (ear temperature ≥ 38 °C, base of the tongue temperature ≥ 37.5 °C, or axillary temperature ≥ 37 °C)
With a pneumonia severity index (PSI) of risk class II or III
Oxygen saturation measured by pulse oximetry (SpO2) ≥ 94% on room air at sea level
Positive test for SARS-CoV-2 or influenza virus infection, confirmed by rapid diagnostic test (excluding cases where both SARS-CoV-2 and influenza virus are positive)
Confirmed lower respiratory tract infection by X-ray
At screening, subjects capable of childbearing must provide a negative serum or urine pregnancy test. These subjects must also commit to adhering to the study-specified contraceptive methods throughout the study duration
Notes: Acceptable contraceptive methods include:
- Established use of oral, injected or implanted hormonal methods of contraception
- Placement of an intrauterine device (IUD) or intrauterine system (IUS)
- Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps)
The participant (or legal representative) agrees and is able to adhere to study protocol-stated requirements, instructions, and restrictions in the investigator's judgement. Furthermore, the participant is capable of understanding and has signed the IRB-approved Informed Consent Form (ICF)
With at least two of the risk factors listed below: Age ≥ 50 years-old; cancer and a life expectancy of ≥ 6 months; HIV infection; immunocompromised patient; congestive heart failure (CHF), or coronary artery disease (CAD), or cardiomyopathies; chronic kidney disease (CKD); chronic liver disease; chronic lung disease; diabetes mellitus (DM); body mass index (BMI) > 25 kg/m2; asthma; cerebrovascular disease; cystic fibrosis; dementia; or current and former smoker

Exclusion criteria

Exclusion Criteria

Subject received investigational treatment within 30 days prior to the study, or concurrent use of another investigational drug
Subject has a history of severe renal disease (required phosphate binders or dialysis)
Subject has chronic diarrhea, characterized by three or more loose stools daily for a minimum of four weeks
High likelihood of mortality within the next 48 hours, as assessed by the investigator
Subject showing signs of respiratory failure and mechanical ventilation is required
Subject with liver cirrhosis
Subject with hepatitis B and/or hepatitis C disease, unless the subject has an aspartate aminotransferase (AST) level ranging from 8 to 31 U/L and an alanine aminotransferase (ALT) level from 0 to 41 U/L
Known active tuberculosis
Current documented bacterial infection
Subject has a documented anaphylactic reaction, regardless of cause
Subject who has taken an antiviral agent against respiratory viral infection for a continuous duration of more than 24 hours before screening
Subject is with active gastrointestinal diseases including gastritis, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis
Subjects received warfarin within 14 days prior to screening or intend to during the screening or treatment phase
History of allergic reactions to any of the ingredients or components used in the manufacture of CX-4945
Women who are pregnant or breastfeeding, or planning pregnancy during the study
Note: Men and women of reproductive potential must commit to effective contraception methods or abstinence during the study. Any resulting pregnancies or suspected pregnancies must be reported to the treating physician immediately.
ALT or AST levels > 5 times upper limit of normal (ULN)
eGFR \<30 mL/min/1.73m2 (calculated by the MDRD formula)
Absolute neutrophil count (ANC) \<1000/μL
Have received treatment with a SARS-CoV-2 specific monoclonal antibody
Have received convalescent COVID-19 plasma treatment
Concurrent use of baricitinib
Any physical findings or illness history that may compromise study results or increase patient risk, as determined by the investigator

Study design

Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment: 45 participants (actual)

Study arms

Experimental
SARS-CoV-2 domain: CX-4945 (400 mg BID for 5 days) +SOC
Notes: The SOC within the SARS-CoV-2 domain is defined as the medications in use at each respective site for the treatment of CAP related to SARS-CoV-2 infection.
Drug: CX-4945 (SARS-CoV-2 domain)
Placebo comparator
SARS-CoV-2 domain: Placebo + SOC
Notes: The SOC within the SARS-CoV-2 domain is defined as the medications in use at each respective site for the treatment of CAP related to SARS-CoV-2 infection.
Drug: Placebo (SARS-CoV-2 domain)
Experimental
Influenza virus domain: CX-4945 (400 mg BID for 5 days) +SOC
Notes: The SOC within the influenza virus domain is defined as the medications in use at each respective site for the treatment of CAP related to influenza virus infection.
Drug: CX-4945 (Influenza virus domain)
Placebo comparator
Influenza virus domain: Placebo + SOC
Notes: The SOC within the influenza virus domain is defined as the medications in use at each respective site for the treatment of CAP related to influenza virus infection.
Drug: Placebo (Influenza virus domain)

Interventions

DrugCX-4945 (SARS-CoV-2 domain)
CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
Also known as: Silmitasertib
DrugPlacebo (SARS-CoV-2 domain)
The dosage and frequency is the same as active drug.
DrugCX-4945 (Influenza virus domain)
CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
Also known as: Silmitasertib
DrugPlacebo (Influenza virus domain)
The dosage and frequency is the same as active drug.

What researchers measure

Primary outcomes

The Percentage of Subjects Requiring Hospitalization, Including Emergency Room Visits, or Resulting in Death Due to Progression of CAP Related to SARS-CoV-2 or Influenza.
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared to placebo plus SOC, in preventing the progression of CAP associated with SARS-CoV-2 and influenza virus infection
Time frame: Day 1 to Day 29

Secondary outcomes

The Percentage of Subjects With All Cause Hospitalization, Emergency Room Visits, or Death During Study Period.
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition
Time frame: Day 1 to Day 29
The Percentage of Subjects With Improved Pulmonary X-ray Findings for Pneumonia, Relative to Baseline or Showing a Return to Normalcy
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition. Note: Visit 3 and its associated efficacy/safety assessments were scheduled for Day 5 in protocol version 1.0 and for Day 7 since protocol version 2.0.
Time frame: Baseline to Day 5/7
The Symptom Resolution for Fever is Defined as Body Temperature Lower Than the Following Definition for 24 Hours (Ear Temperature < 38 °C, Base of the Tongue Temperature < 37.5 °C, or Axillary Temperature < 37 °C)
Time to Symptom Resolution for Fever \[days\]. The symptom resolution for fever is defined as body temperature lower than the following definition (ear temperature \< 38 °C, base of the tongue temperature \< 37.5 °C, or axillary temperature \< 37 °C) Note: Visit 3 and its associated efficacy/safety assessments were scheduled for Day 5 in protocol version 1.0 and for Day 7 since protocol version 2.0.
Time frame: Day 1 to Day 5/7
Change From Baseline in SpO2/FiO2 Ratio
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition Note: Visit 3 and its associated efficacy/safety assessments were scheduled for Day 5 in protocol version 1.0 and for Day 7 since protocol version 2.0.
Time frame: Day 1 to Day 5/7, 15, and 29
The Percentage of Subjects Exhibiting Disease Progression in Health Status Disease Progression is Defined as an Increase of Score on the National Institute of Allergy and Infectious Diseases (NIAID) 8-point Ordinal Scale
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition. NIAID 8-point ordinal scale range: 1-8, with higher scores indicating a worse condition. Note: Visit 3 and its associated efficacy/safety assessments were scheduled for Day 5 in protocol version 1.0 and for Day 7 since protocol version 2.0.
Time frame: Day 1 to Day 5/7, 15, and 29
The Percentage of Subjects Exhibiting Health Improvement in Health Status Health Improvement is Defined as a Reduction of Score on the National Institute of Allergy and Infectious Diseases (NIAID) 8-point Ordinal Scale
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition NIAID 8-point ordinal scale range: 1-8, with higher scores indicating a worse condition. Note: Visit 3 and its associated efficacy/safety assessments were scheduled for Day 5 in protocol version 1.0 and for Day 7 since protocol version 2.0.
Time frame: Day 1 to Day 5/7, 15, and 29

Results

Posted Jan 8, 2026

Limitations and caveats

This trial was terminated early on March 31, 2025 due to insufficient differentiation of the primary endpoint in addressing the unmet medical need, as well as recruitment difficulties caused by the end of the flu season.

Participant flow

Participants were recruited from individuals diagnosed with Community-Acquired Pneumonia (CAP) associated with SARS-CoV-2 and influenza viral infections at seven sites across Taiwan between February 2024 and March 2025. The first participant was enrolled on March 20, 2024, and the last on February 27, 2025.

Participant flow — Overall Study
Milestone	SARS-CoV-2 Domain: CX-4945 + SOC	SARS-CoV-2 Domain: Placebo + SOC	Influenza Virus Domain: CX-4945 + SOC	Influenza Virus Domain: Placebo + SOC
Started	15	15	7	7
Completed	15	14	6	6
Not completed	0	1	1	1
Withdrew: Withdrawal by subject	0	1	0	1
Withdrew: Adverse event	0	0	1	0

Outcome measures

PrimaryThe Percentage of Subjects Requiring Hospitalization, Including Emergency Room Visits, or Resulting in Death Due to Progression of CAP Related to SARS-CoV-2 or Influenza.

To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared to placebo plus SOC, in preventing the progression of CAP associated with SARS-CoV-2 and influenza virus infection

Time frame:: Day 1 to Day 29
Reported as:: Count of participants · Participants

The Percentage of Subjects Requiring Hospitalization, Including Emergency Room Visits, or Resulting in Death Due to Progression of CAP Related to SARS-CoV-2 or Influenza.
Participants	SARS-CoV-2 domain: CX-4945 + SOC	SARS-CoV-2 domain: Placebo + SOC	Influenza virus domain: CX-4945 + SOC	Influenza virus domain: Placebo + SOC
The Percentage of Subjects Requiring Hospitalization, Including Emergency Room Visits, or Resulting in Death Due to Progression of CAP Related to SARS-CoV-2 or Influenza.	0	0	0	0

SecondaryThe Percentage of Subjects With All Cause Hospitalization, Emergency Room Visits, or Death During Study Period.

To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition

Time frame:: Day 1 to Day 29
Reported as:: Count of participants · Participants

The Percentage of Subjects With All Cause Hospitalization, Emergency Room Visits, or Death During Study Period.
Participants	SARS-CoV-2 domain: CX-4945 + SOC	SARS-CoV-2 domain: Placebo + SOC	Influenza virus domain: CX-4945 + SOC	Influenza virus domain: Placebo + SOC
The Percentage of Subjects With All Cause Hospitalization, Emergency Room Visits, or Death During Study Period.	0	1	1	0

SecondaryThe Percentage of Subjects With Improved Pulmonary X-ray Findings for Pneumonia, Relative to Baseline or Showing a Return to Normalcy

To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition. Note: Visit 3 and its associated efficacy/safety assessments were scheduled for Day 5 in protocol version 1.0 and for Day 7 since protocol version 2.0.

Time frame:: Baseline to Day 5/7
Reported as:: Count of participants · Participants

The Percentage of Subjects With Improved Pulmonary X-ray Findings for Pneumonia, Relative to Baseline or Showing a Return to Normalcy
Participants	SARS-CoV-2 domain: CX-4945 + SOC	SARS-CoV-2 domain: Placebo + SOC	Influenza virus domain: CX-4945 + SOC	Influenza virus domain: Placebo + SOC
Day 5/7 — Worsen	1	1	1	0
Day 5/7 — No change	1	1	3	0
Day 5/7 — Improved	8	7	1	5
Day 5/7 — Normal	5	6	2	1
Day 15 — Worsen	0	0	0	0
Day 15 — No change	1	0	0	0
Day 15 — Improved	5	5	3	2
Day 15 — Normal	9	9	3	4
Day 29 — Worsen	0	0	0	0
Day 29 — No change	0	0	0	0
Day 29 — Improved	1	0	2	0
Day 29 — Normal	14	14	4	6

SecondaryThe Symptom Resolution for Fever is Defined as Body Temperature Lower Than the Following Definition for 24 Hours (Ear Temperature < 38 °C, Base of the Tongue Temperature < 37.5 °C, or Axillary Temperature < 37 °C)

Time to Symptom Resolution for Fever \[days\]. The symptom resolution for fever is defined as body temperature lower than the following definition (ear temperature \< 38 °C, base of the tongue temperature \< 37.5 °C, or axillary temperature \< 37 °C) Note: Visit 3 and its associated efficacy/safety assessments were scheduled for Day 5 in protocol version 1.0 and for Day 7 since protocol version 2.0.

Time frame:: Day 1 to Day 5/7
Reported as:: Median · days

The Symptom Resolution for Fever is Defined as Body Temperature Lower Than the Following Definition for 24 Hours (Ear Temperature < 38 °C, Base of the Tongue Temperature < 37.5 °C, or Axillary Temperature < 37 °C)
days	SARS-CoV-2 domain: CX-4945 + SOC	SARS-CoV-2 domain: Placebo + SOC	Influenza virus domain: CX-4945 + SOC	Influenza virus domain: Placebo + SOC
The Symptom Resolution for Fever is Defined as Body Temperature Lower Than the Following Definition for 24 Hours (Ear Temperature < 38 °C, Base of the Tongue Temperature < 37.5 °C, or Axillary Temperature < 37 °C)	1.8 (NA to NA)	1.2 (NA to NA)	1.8 (1.20 to NA)	1.7 (1.50 to NA)

SecondaryChange From Baseline in SpO2/FiO2 Ratio

To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition Note: Visit 3 and its associated efficacy/safety assessments were scheduled for Day 5 in protocol version 1.0 and for Day 7 since protocol version 2.0.

Time frame:: Day 1 to Day 5/7, 15, and 29
Reported as:: Mean · ratio change

Change From Baseline in SpO2/FiO2 Ratio
ratio change	SARS-CoV-2 domain: CX-4945 + SOC	SARS-CoV-2 domain: Placebo + SOC	Influenza virus domain: CX-4945 + SOC	Influenza virus domain: Placebo + SOC
Day 5/7	0.95 ± 3.689	0.63 ± 4.359	2.04 ± 4.647	0.68 ± 5.091
Day 15	0.95 ± 2.670	1.36 ± 4.736	3.17 ± 6.506	1.59 ± 3.888
Day 29	1.59 ± 3.446	1.70 ± 6.083	4.76 ± 3.012	2.38 ± 5.832

SecondaryThe Percentage of Subjects Exhibiting Disease Progression in Health Status Disease Progression is Defined as an Increase of Score on the National Institute of Allergy and Infectious Diseases (NIAID) 8-point Ordinal Scale

To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition. NIAID 8-point ordinal scale range: 1-8, with higher scores indicating a worse condition. Note: Visit 3 and its associated efficacy/safety assessments were scheduled for Day 5 in protocol version 1.0 and for Day 7 since protocol version 2.0.

Time frame:: Day 1 to Day 5/7, 15, and 29
Reported as:: Count of participants · Participants

The Percentage of Subjects Exhibiting Disease Progression in Health Status Disease Progression is Defined as an Increase of Score on the National Institute of Allergy and Infectious Diseases (NIAID) 8-point Ordinal Scale
Participants	SARS-CoV-2 domain: CX-4945 + SOC	SARS-CoV-2 domain: Placebo + SOC	Influenza virus domain: CX-4945 + SOC	Influenza virus domain: Placebo + SOC
Day 5/7	0	0	0	0
Day 15	0	0	1	0
Day 29	0	0	0	0

SecondaryThe Percentage of Subjects Exhibiting Health Improvement in Health Status Health Improvement is Defined as a Reduction of Score on the National Institute of Allergy and Infectious Diseases (NIAID) 8-point Ordinal Scale

To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition NIAID 8-point ordinal scale range: 1-8, with higher scores indicating a worse condition. Note: Visit 3 and its associated efficacy/safety assessments were scheduled for Day 5 in protocol version 1.0 and for Day 7 since protocol version 2.0.

Time frame:: Day 1 to Day 5/7, 15, and 29
Reported as:: Count of participants · Participants

The Percentage of Subjects Exhibiting Health Improvement in Health Status Health Improvement is Defined as a Reduction of Score on the National Institute of Allergy and Infectious Diseases (NIAID) 8-point Ordinal Scale
Participants	SARS-CoV-2 domain: CX-4945 + SOC	SARS-CoV-2 domain: Placebo + SOC	Influenza virus domain: CX-4945 + SOC	Influenza virus domain: Placebo + SOC
Day 5/7	2	1	2	1
Day 15	4	2	2	1
Day 29	5	2	2	1

Adverse events

Collected over From randomization until end of follow-up, up to 32 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
Group	Deaths	Serious	Other
SARS-CoV-2 Domain: CX-4945 + SOC	0/15 (0%)	0/15 (0%)	10/15 (66.7%)
SARS-CoV-2 Domain: Placebo + SOC	0/15 (0%)	0/15 (0%)	4/15 (26.7%)
Influenza Virus Domain: CX-4945 + SOC	0/7 (0%)	1/7 (14.3%)	5/7 (71.4%)
Influenza Virus Domain: Placebo + SOC	0/7 (0%)	0/7 (0%)	5/7 (71.4%)

Most frequent serious events

Most frequent serious events
Event	SARS-CoV-2 Domain: CX-4945 + SOC	SARS-CoV-2 Domain: Placebo + SOC	Influenza Virus Domain: CX-4945 + SOC	Influenza Virus Domain: Placebo + SOC
Pneumonia bacterialInfections and infestations	0/15	0/15	1/7	0/7

Most frequent other events

Showing 10 of 33

Most frequent other events
Event	SARS-CoV-2 Domain: CX-4945 + SOC	SARS-CoV-2 Domain: Placebo + SOC	Influenza Virus Domain: CX-4945 + SOC	Influenza Virus Domain: Placebo + SOC
DiarrhoeaGastrointestinal disorders	7/15	1/15	4/7	3/7
NauseaGastrointestinal disorders	4/15	1/15	1/7	0/7
ConstipationGastrointestinal disorders	0/15	0/15	1/7	1/7
Mouth ulcerationGastrointestinal disorders	0/15	0/15	0/7	1/7
DysphoniaRespiratory, thoracic and mediastinal disorders	1/15	0/15	1/7	0/7
CoughRespiratory, thoracic and mediastinal disorders	0/15	0/15	1/7	0/7
EpistaxisRespiratory, thoracic and mediastinal disorders	0/15	0/15	1/7	0/7
Nasal congestionRespiratory, thoracic and mediastinal disorders	0/15	0/15	1/7	0/7
Oropharyngeal painRespiratory, thoracic and mediastinal disorders	0/15	0/15	1/7	0/7
RhinorrhoeaRespiratory, thoracic and mediastinal disorders	0/15	0/15	1/7	0/7

Baseline characteristics

The ITT population is defined as all randomized subjects who received at least one dose of Silmitasertib (CX-4945) or placebo. This population was used as the primary analysis population for efficacy endpoints and the analysis population for baseline data, safety and exploratory endpoints.

Age, Continuous
Age, Continuous(years)	SARS-CoV-2 Domain: CX-4945 + SOC	SARS-CoV-2 Domain: Placebo + SOC	Influenza Virus Domain: CX-4945 + SOC	Influenza Virus Domain: Placebo + SOC	Total
Mean	46.3 ± 11.88	47.4 ± 11.04	48.6 ± 13.35	49.0 ± 14.33	47.5 ± 11.84

Sex: Female, Male
Sex: Female, Male(Participants)	SARS-CoV-2 Domain: CX-4945 + SOC	SARS-CoV-2 Domain: Placebo + SOC	Influenza Virus Domain: CX-4945 + SOC	Influenza Virus Domain: Placebo + SOC	Total
Female	9	8	2	4	23
Male	6	7	5	3	21

Race (NIH/OMB)
Race (NIH/OMB)(Participants)	SARS-CoV-2 Domain: CX-4945 + SOC	SARS-CoV-2 Domain: Placebo + SOC	Influenza Virus Domain: CX-4945 + SOC	Influenza Virus Domain: Placebo + SOC	Total
American Indian or Alaska Native	0	0	0	0	0
Asian	15	15	7	7	44
Native Hawaiian or Other Pacific Islander	0	0	0	0	0
Black or African American	0	0	0	0	0
White	0	0	0	0	0
More than one race	0	0	0	0	0
Unknown or Not Reported	0	0	0	0	0

Study locations

7 sites

Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan
Far Eastern Memorial Hospital
New Taipei City, Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan
National Taiwan University Cancer Center, National Taiwan University Hospital
Taipei, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Tri-Service General Hospital
Taipei, Taiwan
Taoyuan General Hospital, Ministry of Health and Welfare
Taoyuan, Taiwan

References and documents

Study documents

Study protocol · Aug 16, 2024
Statistical analysis plan · Jun 25, 2025

Documents are hosted by the registry — open the source record to download them.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT06202521
Lead sponsor: Senhwa Biosciences, Inc.
Responsible party: Sponsor
First posted: Jan 11, 2024
Start date: Mar 20, 2024
Primary completion: Apr 22, 2025
Completion: Apr 22, 2025
Results posted: Jan 8, 2026
Last update: Jan 8, 2026

Study contacts

Jason Huang, M.D.

study chair · Senhwa Biosciences

Oversight

FDA-regulated drug: Yes
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Community-Acquired Pneumonia→

Other studies from this sponsor

Senhwa Biosciences, Inc.

Start the discussion